Release Therapeutics (previously called MaxiVAX) developed a revolutionary, patented, platform technology for the delivery of highly potent therapeutic proteins to the CNS and beyond. Centered on prioritizing patient needs, this novel platform is a promising therapeutic approach, distinguished by its unique CNS-directed functionality and versatile multi-application capabilities.
Looking for a particular MaxiVAX employee's phone or email?
The MaxiVAX annual revenue was $5 million in 2026.
MaxiVAX is based in Genève, Genève.
The NAICS codes for MaxiVAX are [32541, 32, 325, 3254].
The SIC codes for MaxiVAX are [28, 2834, 283].